PH

Pharmena SAWSE Pharmena Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Sep, 2024

Last price

Market cap $B

0.017

Micro

Exchange

XWAR - Warsaw Stock Exchange

PHR.WA Stock Analysis

PH

Uncovered

Pharmena SA is uncovered by Eyestock quantitative analysis.

Market cap $B

0.017

Dividend yield

9.77 %

Shares outstanding

11.138 B

PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. The company is headquartered in Lodz, Woj. Lodzkie and currently employs 24 full-time employees. The company went IPO on 2008-08-25. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.

View Section: Eyestock Rating